On January 5, the Danish pharmaceutical company Novo Nordisk launched the Wegovy pill for the first time in the United States. Part of a wave of FDA-approved obesity treatments, the prescription medication helps people lose weight by targeting the GLP-1 receptor.. By January 16, the pill had already been prescribed over 18,000 times, showcasing its immense popularity.
Wegovy medications contain semaglutide, the same compound found in similar medicines such as Ozempic and Rybelsus. Semaglutide works by mimicking the hormone GLP-1, which helps regulate hunger by reducing appetite, slowing digestion, and helping people feel full longer. It is intended to be taken alongside regular exercise and a healthier diet rather than as a standalone cure to obesity.
Prior to this year, Nova Nordisk only offered Wegovy as a patient-administered injection pen. Its new once-a-day product is significant as the first obesity medication of its type, overtaking competitors that require monthly or even weekly injections.. People who fear needles or prefer the simplicity of pills will likely prefer this product . Additionally, results from a study published by the New England Journal of Medicine found that the pill form is about as effective as the injection form. Patients who took the pills over a period of 64 weeks experienced similar amounts of weight loss as those who took the injection form of Wegovy over 68 weeks. In another study done by the New England Journal of Medicine, people who took the injection form of Wegovy and had lifestyle changes lost as much as 15% of their body weight on average within 68 weeks. This translates to an average of 33 pounds lost.
However, the medication does come with risks. Because the pill reduces your appetite, it is possible for patients to accidentally eat too little, causing protein and micronutrient deficiencies which can also lead to muscle loss. To add to this, some potential serious side effects include changes in vision, irregular heartbeat, depression, severe allergic reactions, and even thyroid cancer.
Despite these risks, Novo Nordisk continues to aggressively market the Wegovy pill as a simple, affordable alternative to competitors like Zepbound and Mounjaro. Without insurance, the pill starts at around $149 each month, while private insurance coverage lowers it to just $25 a month. Though this price tag is definitely significant, it is still a sharp discount from the thousand-dollar prices charged by other pharmaceuticals. All of this is part of Novo Nordisk’s plan to attract cash-paying consumers without insurance coverage, a sharp contrast to the mainstream business model.
As the new pill turns a month old on the U.S. market, it awaits approval from other countries. Whether the pill becomes a lasting treatment or a short-lived breakthrough depends on further research and the success of Novo Nordisk’s strategy.
Be First to Comment